GlaxoSmithKline (CAI:BIOC) Total Equity: E£2,108.9 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is GlaxoSmithKline Total Equity?

GlaxoSmithKline CAI:BIOC -2.43% Total Equity is E£2,108.9 Mil as of Mar. 2025.

GlaxoSmithKline's total equity for the quarter that ended in Mar. 2025 was E£2,108.9 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

GlaxoSmithKline Total Equity Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Total Equity Chart

GlaxoSmithKline Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 980.93 1,002.83 951.47 1,048.29 1,079.83

GlaxoSmithKline Quarterly Data
Jun17 Sep17 Dec17 Mar18 Sep18 Dec18 Mar19 Jun19 Sep19 Mar20 Mar21 Jun21 Sep21 Mar22 Jun22 Mar23 Jun23 Sep23 Mar24 Mar25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,959.30 1,924.44 1,951.60 1,882.26 2,108.94

GlaxoSmithKline Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

GlaxoSmithKline's Total Equity for the fiscal year that ended in Dec. 2018 is calculated as

Total Equity=Total Assets(Q: Dec. 2018 )-Total Liabilities(Q: Dec. 2018 )
=2039.624345-959.796813
=1,079.8

GlaxoSmithKline's Total Equity for the quarter that ended in Mar. 2025 is calculated as

Total Equity=Total Assets(Q: Mar. 2025 )-Total Liabilities(Q: Mar. 2025 )
=4661.995568-2553.053134
=2,108.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of E£2,108.9 Mil mean?
GlaxoSmithKline (CAI:BIOC) has a Total Equity of E£2,108.9 Mil as of Mar. 2025. The total amount of equity as record on a company's balance sheet. View historical data for GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's Total Equity too high?
GlaxoSmithKline's current Total Equity is E£2,108.9 Mil.
How does GlaxoSmithKline's Total Equity compare to PRPH?
GlaxoSmithKline's Total Equity of E£2,108.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for GlaxoSmithKline and its competitors. GlaxoSmithKline's current Total Equity is E£2,108.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current Total Equity of E£2,108.9 Mil. The current Total Equity is E£2,108.9 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current Total Equity is E£2,108.9 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlaxoSmithKline Business Description

Address Boomerang Building, No 46, Block (J) First Section City Centre, Town Centre, Second floor, Fifth District - New Cairo, Cairo, EGY, 11835
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.